Lombard Medical, Inc. (EVARF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.64: the stock has moved about 36% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerLombard Medical, Inc. (EVARF) trades at $0.0001. Lombard Medical, Inc. specializes in developing and marketing endovascular stent-grafts for aortic aneurysm repair. Their primary product, Aorfix, addresses challenging anatomies, while they also offer solutions for standard cases. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for EVARF: EVARF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Lombard Medical, Inc. (EVARF) Healthcare & Pipeline Overview
Lombard Medical, Inc. focuses on endovascular stent-grafts, particularly Aorfix for complex aortic aneurysms. With a global presence and direct sales model, the company competes in the medical device industry, facing challenges in a market with established players and stringent regulatory requirements, reflected in its negative profit margin.
What Is the Investment Thesis for EVARF?
Lombard Medical, Inc. presents a focused investment opportunity within the medical device sector, specifically in the endovascular aneurysm repair market. The company's Aorfix stent-graft addresses a niche segment of AAAs with challenging anatomies, potentially offering a competitive advantage. However, the company's negative profit margin of -255.0% and small market capitalization raise concerns about its financial sustainability. Growth catalysts include expanding market penetration in existing geographies and potential regulatory approvals in new markets. Investors should carefully consider the company's financial position, competitive landscape, and regulatory hurdles before making investment decisions. The company's beta of 0.64 suggests lower volatility than the overall market.
Based on FMP financials and quantitative analysis
EVARF Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with potential for high growth but also significant risk.
- Negative P/E ratio of -0.00 reflects the company's current lack of profitability.
- Profit Margin of -255.0% signals significant operational challenges and potential financial instability.
- Gross Margin of 7.8% suggests limited pricing power and high cost of goods sold.
- Beta of 0.64 indicates lower volatility compared to the overall market, which may appeal to risk-averse investors.
Who Are EVARF's Competitors?
EVARF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| NVNO enVVeno Medical Corporation | $8.10 | +0.75% | $5.63M | 33 5-pillar |
| BJDX Bluejay Diagnostics, Inc. | $0.84 | -1.12% | 30 5-pillar | |
| BDMD Baird Medical Investment Holdings Limited | $0.75 | +0.91% | $31.7M | — |
| SNWV SANUWAVE Health, Inc. | $4.82 | +4.33% | $41.5M | 36 5-pillar |
| SRTS Sensus Healthcare, Inc. | $2.98 | +1.02% | $49.1M | 31 5-pillar |
| HYPD Hyperion DeFi, Inc. | $3.73 | +1.91% | $56.5M | 36 5-pillar |
| LNSR LENSAR, Inc. | $6.75 | +2.74% | $82.9M | 45 5-pillar |
| APYX Apyx Medical Corporation | $2.55 | +2.00% | $107M | 33 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EVARF's Key Strengths?
Specialized Aorfix stent-graft for complex anatomies.
- Proprietary delivery systems for precise placement.
- Direct sales force and distributor network.
- Focus on state-owned and government-owned hospitals.
What Are EVARF's Weaknesses?
Negative profit margin and small market capitalization.
- Limited product portfolio compared to larger competitors.
- Reliance on a few key products.
- Dependence on regulatory approvals for market expansion.
What Are the Key Risks for EVARF?
Increased competition from larger medical device companies.
- Delays in regulatory approvals.
- Negative profit margin and financial instability.
- Limited liquidity due to OTC listing.
- Technological obsolescence.
What Threats Does EVARF Face?
- Competition from larger, established medical device companies.
- Stringent regulatory requirements and potential delays in approvals.
- Technological obsolescence.
- Economic downturns and healthcare budget constraints.
What Are EVARF's Competitive Advantages?
- Proprietary Aorfix stent-graft designed for complex anatomies.
- Specialized delivery systems for precise stent-graft placement.
- Established relationships with state-owned and government-owned hospitals.
- Intellectual property protection for key technologies.
What Does EVARF Do?
Founded in 2000 and headquartered in Didcot, UK, Lombard Medical, Inc. is a medical technology company focused on designing, manufacturing, and marketing advanced endovascular stent-grafts for the repair of aortic aneurysms. The company's flagship product, Aorfix, is a unique endovascular stent-graft specifically engineered for the treatment of abdominal aortic aneurysms (AAAs) with significant angulation at the neck of the aneurysm, up to 90 degrees. This addresses a critical need in treating patients with challenging anatomies. In addition to Aorfix, Lombard Medical offers the Altura endovascular stent graft system, designed for standard AAA anatomies. The company also provides specialized delivery systems, including the Aorflex delivery system for precise Aorfix placement and the IntelliFlex LP delivery system to enhance control during deployment. Lombard Medical distributes its products through a direct sales force and distributors, primarily targeting state-owned or government-owned hospitals across the United States, the United Kingdom, Germany, Japan, and other international markets. The company operates in a competitive landscape, facing established medical device companies.
What Products and Services Does EVARF Offer?
- Develops endovascular stent-grafts for aortic aneurysm repair.
- Manufactures Aorfix stent-graft for complex abdominal aortic aneurysms.
- Markets Aorfix and Altura stent-graft systems globally.
- Provides Aorflex and IntelliFlex delivery systems for precise stent-graft placement.
- Sells products directly and through distributors.
- Targets state-owned and government-owned hospitals.
How Does EVARF Make Money?
- Develops and manufactures endovascular stent-grafts.
- Sells products directly through a sales force and distributors.
- Generates revenue from stent-graft sales for aortic aneurysm repair.
- Focuses on state-owned and government-owned hospitals as primary customers.
What Industry Does EVARF Operate In?
Lombard Medical operates within the global medical device industry, specifically targeting the endovascular aneurysm repair (EVAR) market. This market is driven by an aging population, increasing prevalence of aortic aneurysms, and technological advancements in minimally invasive procedures. The competitive landscape includes larger, established medical device companies with broader product portfolios. Lombard Medical differentiates itself with its Aorfix stent-graft, designed for complex anatomies. The industry is subject to stringent regulatory requirements and ongoing technological innovation.
Who Are EVARF's Key Customers?
- State-owned hospitals
- Government-owned hospitals
- Vascular surgeons
- Interventional radiologists
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Lombard Medical, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Didcot, GB. The company is led by CEO Kurt Lemvigh. EVARF has traded publicly since 2014.
Key Financial Metrics
Return on assets is -45.8%, showing how much profit it generates from its asset base. A current ratio of 3.33 indicates the company holds enough short-term assets to cover its near-term obligations.
Earnings Track Record
Lombard Medical, Inc. has beaten Wall Street's EPS estimate in 4 of its last 6 reported quarters — more hits than misses. Reported results have landed about 1.9% above estimates on average.
EVARF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
EVARF Latest News
No recent news available for EVARF.
EVARF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for EVARF.
Price Targets
Wall Street price target analysis for EVARF.
EVARF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for EVARF; grades run from A+ (80-100) to F (below 30).
Leadership: Kurt Lemvigh
CEO
Kurt Lemvigh serves as the Chief Executive Officer of Lombard Medical, Inc. His background includes experience in the medical device industry, with a focus on commercialization and market development. Prior to joining Lombard Medical, he held leadership positions at various medical technology companies, where he was responsible for driving revenue growth and expanding market share. He has a proven track record of successfully launching new products and building high-performing teams. His expertise lies in strategic planning, sales and marketing, and business development within the healthcare sector.
Track Record: Since assuming the role of CEO at Lombard Medical, Kurt Lemvigh has focused on streamlining operations, expanding the company's geographic reach, and driving adoption of the Aorfix stent-graft. Key initiatives include strengthening the sales force, establishing new distribution partnerships, and investing in clinical education programs. Under his leadership, the company has faced challenges related to profitability and market competition. His focus remains on achieving sustainable growth and improving financial performance.
EVARF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Lombard Medical may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any regulatory actions or legal disputes.
- Established history in the medical device industry.
- Proprietary technology and products.
- Global presence and distribution network.
- Experienced management team.
Common Questions About EVARF (Healthcare)
What does Lombard Medical, Inc. do?
Lombard Medical, Inc. is a medical technology company that develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms. They also offer the Altura system for standard anatomies.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.